Overview
Tabula Bioscience develops machine learning-driven genetic models to advance personalized medicine and disease prediction, and designs programmable, strain-specific antimicrobials using bacteriophages. Its models use unlabeled genomic data from humans and other organisms, incorporate expert priors and epigenetic information, and rely on probabilistic programming to infer mechanisms rather than just correlations. It differentiates itself by combining data-informed biology with novel ML architectures to enable targeted therapies, especially phage-based solutions for Gram-negative bacteria. Its goal is to close the gap between heritability and prediction in human diseases and enable more effective, individualized treatments.
Work here?Claim your company
Simplify's take
What believers are saying
- Tabula posted active Madison and Bay Area phage roles in 2026.
- August 2026 materials say Tabula is treating real patients six months after launch.
- Tabula’s 2026 stack combines wet-lab validation, NGS, and computational modeling.
What critics are saying
- PitchBook shows only Tabula’s 2022 $2M seed, starving clinical and manufacturing scale.
- Tabula’s 2026 temp-to-hire lab hiring signals manual R&D, not scalable GMP operations.
- A failed phage trial in 2026-2027 destroys financing and platform credibility.
What makes Tabula unique
- Tabula pairs phage wet lab work with ML and physics-based simulation.
- Tabula targets Gram-negative pathogens, including E. coli and Pseudomonas, with programmable antimicrobials.
- Tabula uses unlabeled genomic data, expert priors, and epigenetics for mechanistic models.
Help us improve and share your feedback! Did you find this helpful?